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Objectives MicroRNAs (miRNAs) have been implicated
in the pathogenesis of autoimmune diseases, not least
for their critical role in the regulation of regulatory T cell
(Treg) function. Deregulated expression of miR-146a and
miR-155 has been associated with rheumatoid arthritis
(RA). We therefore investigated miR-146a and miR-155
expression in Tregs of patients with RA and their
possible impact on Treg function and disease activity.
Methods Expression of miR-146a and miR-155 was
assessed in RA patients and controls. MiRNA expression
was correlated with disease activity and expression of
target genes. Interference with biological activity of
miRNAs was evaluated in functional Treg assays.
Results Diminished upregulation of miR-146a and
miR-155 in response to T cell stimulation was found in
Tregs of RA patients. Diminution of miR-146a expression
was observed in particular in patients with active
disease, and correlated with joint inflammation. In
patients with active RA, Tregs demonstrated a pro-
inflammatory phenotype characterised by inflammatory
cytokine expression. This was due to an augmented
expression and activation of signal transducer and
activator transcription 1 (STAT1), a direct target of miR-
146a.
Conclusions Our results suggest that in RA miR-146a
facilitates a pro-inflammatory phenotype of Tregs via
increased STAT1 activation, and contributes thereby to
RA pathogenesis.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune
diseases characterised by synovial inflammation and
a progressive cell-mediated destruction of joints.1
Regulatory CD25 positive CD4 T cells (Tregs)
expressing Foxp3 control the onset and the devel-
opment of autoimmune disease. Their depletion in
mice results in spontaneous development of several
autoimmune diseases like, for example, polyarthri-
tis.2 Although in autoimmune diseases, Tregs are
present in normal frequency and numbers in the
periphery and are even enriched at local sites of
inflammation like the synovium in RA, their sup-
pressive capacity seems to be diminished.3 4 On the
one hand, the pro-inflammatory milieu characteris-
tic for ongoing autoimmune inflammation, in par-
ticular cytokines like tumour necrosis factor (TNF),
IL-6, or IL-21, might attenuate Treg suppressive
capacity.5–8 On the other hand, distinct intrinsic
factors, such as genetic factors, may also contribute
to a diminished suppressive phenotype of Tregs in
RA. For instance, functional polymorphisms in the
Foxp3 gene have been reported to be associated
with susceptibility to several autoimmune dis-
eases.9–11 Moreover, miRNAs have recently been
shown to play a critical role in the regulation of the
immune function of Tregs as Treg-specific ablation
of either one of the two key miRNA-processing
enzymes, Dicer or Drosha, results in severe auto-
immunity in mice.12 13
MiRNAs are about 23nt small non-coding RNAs
that regulate mRNA expression at the post-
transcriptional level by directing mRNA degrad-
ation or transcriptional repression.14 Alterations in
miRNA expression levels impact expression of the
target genes in a 1.2-fold to 4-fold manner, and
represent, therefore, a fine-tuning mechanism regu-
lating protein expression.15 In RA, altered expres-
sion, in particular of two miRNAs, miR-146a and
miR-155, has repeatedly been reported to be asso-
ciated with the disease. Elevated levels of miR-146a
and miR-155 were observed in synovial fibroblasts
from RA patients as well as in RA synovial
tissue.16–18 Alterations in the miR-146a expression
profile were found in total peripheral mononuclear
as well as in CD4 T cells.19 20 Analysis of the
miRNAs in an experimental disease model revealed
that treatment of mice with miR-146a in the course
of collagen-induced arthritis (CIA) prevented joint
destruction,21 whereas miR-155-deficient mice
were completely resistant to the development of
CIA.18 To understand the possible impact of
miRNAs on Treg function in RA, we sought to
analyse whether expression of miR-146a and
miR-155 is altered also in Tregs of RA patients. We
observed miR-146a alterations in Tregs and
miR-155 alterations in CD4 T cells. Alterations in
miR-146a but not miR-155 expression correlated
with disease activity. Moreover, it correlated with
augmented expression and activation of signal
transducer and activator of transcription 1
(STAT1), a direct target of miR-146a, and lead
likely to a pro-inflammatory Treg phenotype sug-
gesting an essential role of miR-146a in regulation




Peripheral blood was obtained from 61 patients
with RA, and 49 age-matched and gender-matched
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healthy individuals (table 1). Patients fulfilled the 2010 EULAR/
American College of Rheumatology (ACR), or the ACR 1987 cri-
teria for RA.22 23 Demographic and clinical parameters, such as
age, gender, disease duration, tender joint count on 28 and on 68
joints (TJC28 and TJC68, respectively), swollen joint count on
28 and on 66 joints (SJC28 and SJC66, respectively), rheumatoid
factor, anticyclic citrullinated peptide antibodies (Ab), disease
activity score in 28 joints (DAS28), C-reactive protein (CRP), and
erythrocyte sedimentation rate (ESR) were collected at the time
of blood sampling. At the study entree 23/61 of patients were
untreated, 17/61 were on steroids either alone or in combin-
ation with disease modifying anti-rheumatic drugs (DMARDs)
and/or biologics, 35/61 were treated with DMARDs (metho-
trexate or leflunomide) either alone or in combination with
prednisolone and/or biologics, and 19/61 were receiving biolo-
gics alone or in combination (TNF inhibitors, tocilizumab,
rituximab, or abatacept). All subjects provided written informed
consent. The study was approved by the Ethics Committee of
the Hospital of the University of Munich.
T cell purification and culture
Tregs and CD25 negative CD4 T cells were purified from human
PBMCs by a human CD4-CD25 regulatory T cell isolation kit
(Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of Tregs
and CD25 negative CD4 T cells was controlled by flow cytometry
using monoclonal Abs to CD3, CD4, CD25, and CD127. Typically,
≥95% of isolated cell populations were CD3/CD4 positive. Tregs
were ≥90% CD25 positive and ∼80% CD127 negative. CD25
negative CD4 T cells were ≥98% negative for CD25 and ≥98%
positive for CD127. The purity and number of the isolated cell
populations were comparable between patients and controls (online
supplementary figure S1). T cells were stimulated with anti-CD3/
CD28-coated beads at a 1:1 cell-to-bead ratio (Dynabeads, Life
Technologies, Carlsbad, California, USA) in the presence of
100 U/mL IL-2 (Chiron, Emeryville, California, USA) in Roswell
Park Memorial Institute (RPMI) 1640 supplemented with 50 U/mL
penicillin G, 50 μg/mL streptomycin, 2 mM L-glutamine (all from
Life Technologies) and 10% normal human serum.
RNA extraction and cDNA synthesis
Total RNA was extracted from T cells using the RNeasy Plus
Mini kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions. 100 to 250 ng RNA were reversely
transcribed into cDNA using AffinityScript QPCR cDNA
Synthesis Kit (Agilent Technologies, La Jolla, California, USA)
according to the manufacturer’s instructions.
Real-time PCR analysis
MiR-146a and miR-155 were detected using TaqMan
MicroRNA assays (Life Technologies). RNU48 was used as an
endogenous cellular short RNA control. MRNA levels were
detected using TaqMan Gene Expression Assays (Life
Technologies). β-actin was used as an endogenous control. PCRs
were performed in duplicates on 7500 Fast Real-Time PCR
System (Life Technologies). Relative quantification was per-
formed based on differences in cross-threshold values (ΔCt)
between the gene of interest and the endogenous control (ie, Ct
(gene of interest)—Ct (endogenous control)). Relative expres-
sion of the gene of interest was calculated according to the
formula 2−ΔCt. To compare expression levels in RA patients and
healthy controls, threshold value was set to a constant number
for each set of experiments.
Luciferase assay
1.2 Mio Tregs were transfected with 5 mg nuclear factor
κ-light-chain-enhancer of activated B cells (NF-κB) luciferase
reporter vector (pGL4.32) and 0.5 mg pRL-TK, a renilla lucifer-
ase control reporter vector, (both from Promega) using an
Amaxa human T cell Nucleofector kit (Lonza, Cologne,
Germany). T cells were distributed into 9 wells of a 96-well
plate (100.000 cell/well), and stimulated with either Dynabeads
in the presence of 50 U/mL IL-2, or with 10 ng/mL phorbol
12-myristat 13-acetat (PMA) (Sigma–Aldrich) and 1 mM iono-
mycin (Merck, Darmstadt, Germany), or left non-stimulated;
17 h after transfection, luciferase activity was measured using a
Dual-Glo luciferase assay (Promega).
Transfection
Tregs were transfected with 1 mM miRNA mimics or antagomirs
using serum-free ACCELL medium (all from Thermo Scientific,
Lafayette, Colorado, USA) for 1 h at 37°C. Threefold excess of
RPMI-1640 medium supplemented with 1 μM miRNA mimics
or antagomirs were added.
STAT1 staining
Freshly isolated or transfected Tregs were stimulated for 24 h
with anti-CD3/28-coated beads. Cells were fixed, permeabilised,
and then stained with PE-labelled anti-STAT1 (1/Stat1) and
Alexa Fluor 647-labelled anti-STAT1 (pS727) (K51-856) (all
from BD Phosflow, San Jose, California, USA).
ELISA
Freshly isolated, or transfected Tregs, were stimulated for 24 h
with anti-CD3/28-coated beads. Levels of IFNγ, TNF and IL-17
in cell culture supernatants were assessed using Quantikine
ELISA according to the manufacturer’s instructions (R&D
Systems, San Diego, California, USA).
T cell suppression assays
CD25 negative CD4 T cells were labelled with 10 mM carboxy-
fluorescein succinimidyl ester (CFSE) (Life Technologies).
MiRNA mimics- or antagomir-transfected Tregs were cultured
with CFSE-labelled CD25 negative CD4 T cells in a 1:1 ratio in
the presence of soluble anti-CD3 and feeder cells for 4 days.
Proliferation of CD25 negative CD4 T cells was assessed by flow
cytometry based on CFSE dilution.
Table 1 Clinical and demographic characteristics of the study
population*
RA patients (n=61) Healthy controls (n=49)
Age, years 56.7±13.1 50.1±8.3
Female/male (n) 48/13 36/13
Disease duration, years 6.7±9.0 N.A.†
RF positive, % 80.3 N.D.‡
Anti-CCP positive, % 80.3 N.D.
DAS28 3.8±1.5 N.A.
TJC28 (n) 4.6±5.3 N.A.
SJC28, (n) 4.5±5.1 N.A.
CRP, mg/dL 1.0±2.0 N.D.
ESR, mm/h 13.9±12.4 N.D.
*Data are shown as mean±SD or absolute numbers.
†N.A., not applicable.
‡N.D., not determined.
Anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease
Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; RA, rheumatoid
arthritis; RF, rheumatoid factor; SJC28, swollen joint count on 28 joints; TJC28, tender
joint count on 28 joints.
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Statistical analyses
Statistical analysis was performed using Prism 5.0 Software for
Macintosh (GraphPad Software, San Diego, California, USA).
Normal distribution was controlled by Kolmogorov–Smirnov.
Differences between study cohorts were determined using
Student t test. Spearman’s rank correlation coefficient was per-
formed to test statistical dependency between two variables;
p<0.05 was considered statistically significant.
RESULTS
Diminished expression levels of miR-146a and miR-155 in
Tregs from RA
Analysis of miR-146a and miR-155 expression in freshly iso-
lated Tregs and CD25 negative CD4 T cells revealed that both
miRNAs were expressed at comparable levels in both cell popu-
lations. There were no differences in the expression levels
between the analysed RA patient cohort and healthy controls
(figure 1A,B).
In response to anti-CD3/CD28 stimulation, expression levels
of miR-146a decreased slightly in Tregs, whereas in CD25 nega-
tive CD4 T cells they were markedly downregulated (figure 1A).
Important was the observation that the expression of miR-146a
in Tregs but not in CD25 negative CD4 T cells was significantly
lower in RA patients than in healthy controls 1 and 2 days after
stimulation. Expression levels of miR-146a in Tregs of RA
patients upon T cell receptor (TCR) stimulation accounted for
about 70% of the expression levels in healthy individuals (see
online supplementary table S1).
By contrast, expression of miR-155 was highly upregulated in
response to anti-CD3/CD28 in Tregs and CD25 negative CD4 T
cells (figure 1B). Still similar to the expression of miR-146a,
expression of miR-155 was significantly lower in RA patients
than in controls 1 and 2 days after stimulation. The diminished
miR-155 expression in RA seemed, however, to be a rather
general characteristic of CD4 T cells and not of Tregs in particu-
lar as it was observed in both T cell populations, Tregs and
CD25 negative CD4 T cells. Yet, in Tregs of RA patients, expres-
sion levels of miR-155 upon T cell receptor (TCR) stimulation
accounted for about 50% of the expression levels in healthy
individuals (see online supplementary table S1).
Different expression levels of miR-146a but not of miR-155
in RA in patient groups stratified based on disease activity
When we stratified the patients based on disease activity into
patients with active disease (DAS28 >3.2) and patients with low
disease activity (DAS28 ≤3.2), we observed a marked difference
in the expression of miR-146a in Tregs (figure 1C). Whereas
Tregs from patients with low disease activity expressed high
levels of miR-146a comparable with that of healthy controls,
Tregs from patients with active disease expressed significantly
lower levels of the miRNA. Tregs from patients with active RA
expressed around 1.5-fold to 2-fold lower levels of miR-146a as
compared to healthy controls or patients with low disease activ-
ity (see online supplementary table S2). No such differences
between patient groups and healthy controls were observed in
CD25 negative CD4 T cells.
Analysis of miR-155 expression revealed that upregulation of
the miRNA after TCR stimulation in Tregs was less pronounced
in both RA patient groups than in healthy individuals (figure
1D). Expression levels of the miRNA were around three-fold
lower in RA Tregs than in healthy controls without a difference
between the patient groups (see online supplementary table S2).
A similar trend was observed in CD25 negative CD4 T cells.
Expression levels of miR-146a correlate with clinical
parameters of disease activity
Because of the Treg-characteristic expression pattern of
miR-146a in RA, we next carried out a correlation analysis
between clinical parameters and expression levels of miR-146a
in Tregs (figure 2). Indeed, there was an inverse correlation
between DAS28 and the expression levels of miR146a (figure
2A). Also, SJC28, SJC66 and TJC28, TJC68 correlated nega-
tively with miR-146a expression (figure 2B,C). By contrast,
there were no such apparent correlations between CRP or ESR
and miR-146a expression expression (figure 2D,E). This con-
firms our observation that in RA, expression of miR-146a levels
in Treg correlates with disease activity.
MiR-146a and miR-155 expression levels in RA do not
correlate with expression of their target genes involved in
NF-κB signalling
Both miRNAs, miR-146a and miR-155, have been reported to
be involved in a negative feedback loop regulating the NF-κB
signalling pathway.24 We, therefore, next investigated expression
of their target genes within the NF-κB activation pathway in
Tregs from RA patients with active disease and with low disease
activity (figure 3). MiR-146a has been reported to regulate
expression of interleukin-1 receptor-associated kinase 1 (IRAK1)
and TNF receptor associated factor 6 (TRAF6),25 whereas
miR-155 targets I-κ B kinase epsilon (IKKe).26 Expression of
the IRAK1 mRNA was upregulated in response to anti-CD3/
CD28 stimulation (figure 3A). By contrast, expression of
TRAF6 and IKKε was rather down-regulated (figure 3B,C).
Interestingly, expression levels of these three genes were gen-
erally higher in RA patients as compared with healthy con-
trols independent of disease activity. NF-κB activity was,
however, comparable between patients and controls (figure
3D). No correlation was, therefore, observed between the
expression levels of miR-146a or miR-155 and the NF-κB
signalling pathway (online supplementary figures S2A,B, 3A).
Correlation of miR-146a expression levels with expression
of STAT1 but not of miR-155 with suppressor of cytokine
signalling 1 (SOCS1)
When we analysed the expression of two other genes reported
to be regulated by miR-146a and miR-155 in particular in
Tregs, STAT1 and SOCS1,27–29 we observed a striking upregula-
tion of their mRNA expression in response to TCR stimulation
from Tregs in patients with active disease but not in healthy con-
trols, and not in the RA patient group with low disease activity
(figure 4A). The upregulation of STAT1 mRNA in the active
group of patients but not in patients with low disease activity
correlated well with the downregulation of miR-146 expression
in Tregs in patients with active disease but not with low disease
activity (figure 1C, supplementary figure S2C). Moreover,
higher STAT1 protein expression and phosphorylation in
response to stimulation in patients with active disease was
observed (figure 4B).
Expression of SOCS1 (figure 4A), a target of miR-155, in
Tregs did not correspond with the expression pattern of
miR-155 shown in figure 1D (see online supplementry figure
S3C). Whereas the active RA group demonstrated an increase in
SOCS1 expression and a simultaneous down-regulation of
miR-155, patients with low disease activity showed diminished
expression of both (figures 1D, 4A), indicating an additional
mechanism controlling SOCS1 expression.
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Altered cytokine secretion pattern in Tregs from patients
with active RA
Alterations in the expression of miR-146a or miR-155, and subse-
quently of STAT1 and SOCS1, might modify cytokine secretion
profiles of CD4 Tcells.27 30 31 We, therefore, next analysed expres-
sion of the pro-inflammatory cytokines, IFNγ, TNF, IL-17 and
IL-2, in Tregs from RA patients stratified again according to their
disease activity (figure 4C). In response to anti-CD3/CD28 stimu-
lation, all cytokines were upregulated in Tregs at mRNA level
within 24 h and downregulated after 48 h. Strikingly, however,
upregulation of cytokine expression was more pronounced in
Tregs from RA patients with active disease than in healthy controls
or in patients with low disease activity. Patients with low disease
activity expressed even diminished levels of the pro-inflammatory
cytokines in comparison with healthy controls. The increase of
cytokine mRNA after 24 h of stimulation in Tregs of patients with
active disease was reflected by cytokine concentrations in cell
culture supernatants (figure 4D). These data together indicate that
in RA, changes in miR-146a or miR-155 expression might indeed
lead to alterations in the Treg phenotype.
Cytokine secretion pattern, but not the suppressive capacity
of Tregs correlates with miR-146 and miR-155 expression
To verify this hypothesis we next analysed cytokine expression in
Tregs treated with either mimics or antagomirs of miR-146a and
miR-155 (figure 5A). Indeed, treatment with mimics of miR-146a
Figure 1 MiR-146a and miR-155 expression levels in Tregs and CD25 negative CD4 T cells. Tregs and CD25 negative CD4 T cells were isolated
and stimulated with anti-CD3/CD28 beads for a total of 2 days. MiRNA expression was assessed in freshly isolated (d0) and in stimulated cells at
24 h (d1) and 48 h (d2) by real-time PCR using TaqMan gene expression assays. MiRNA expression in relation to expression levels of RNU48 is
demonstrated. Expression levels of miR-146a (A) and of miR-155 (B) in 24 healthy controls (HC) and 19 patients with rheumatoid arthritis (RA).
(C, D) Expression of miR-146a (C) and miR-155 (D) in 24 HC and in RA patient stratified according to disease activity: patients with active
disease—RA DAS28 >3.2 (n=8) and patients with low disease activity—RA DAS28 ≤3.2 (n=11). Data are shown as box plots demonstrating
minimum, maximum, median and 25th and 75th percentiles. *p<0.05, **p<0.01, ***p<0.001 by Student t test.
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reduced cytokine secretion, whereas mimics of miR-155 increased
the cytokine production. Neutralisation of the miRNA effects
through antagomirs led to opposite results. Interestingly, however,
once both miRNAs were mimicked or neutralised simultaneously,
the cytokine secretion profile was rather similar to that observed
during manipulation of miR-146a (figure 5A). The intervention
with miR-146a led also to significant alterations in STAT1 expres-
sion and phosphorylation (figure 5B). Whereas mimicking of
miR-146a diminished STAT1 expression and phosphorylation,
neutralisation of the miRNA increased both. Remarkably, despite
the pronounced effect on cytokine expression profile, intervention
with the expression of these two miRNAs did not affect the in
vitro suppressive capacity of Tregs (figure 5C).
DISCUSSION
Based on the apparent deregulation of miR-146a and miR-155
expression in RA and, moreover, their critical involvement in the
onset of arthritis in animal models, we have investigated in the
current study expression of miR-146a and miR-155 in Tregs, and
have analysed their impact on Treg function in patients with RA.
We observed a diminished expression of both miRNAs,
miR-146a and miR-155, in Tregs of patients indicating some
disease-dependent abnormalities in the regulation of their
expression. MiR-146a and miR-155 are widely expressed and
are involved in the differentiation and activation of both, the
innate and the adaptive immune systems.32 In particular,
miR-146a has been initially reported to be upregulated in
macrophages in response to TLR-mediated NF-κB signal-
ling.25 33 MiR-146a seems to be an important player in the
NF-κB signalling pathway in innate immunity as it downregu-
lates the NF-κB signalling transducers, IRAK1 and TRAF6 and,
thereby, calms NF-κB signals. Observations from
miR-146a-deficient mice suggest that also in CD4 and CD8 T
cells, miR-146a might be upregulated in response to
TCR-mediated NF-κB signalling and, in turn, might downregu-
late NF-κB activity through repressing IRAK1 and TRAF6.34
Interestingly, however, we did not observe an upregulation of
miR-146a in response to TCR stimulation, either in Tregs or in
CD25 negative CD4 T cells, despite NF-κB-activation that
occurred in response to our stimulatory conditions (figures 1A,
3D). The human origin of the cells in our study allows us, there-
fore, to suggest different signalling pathways downstream of
TCR signalling in CD4 T cells in humans than in mice that
result in miR-146a expression. Moreover, evidence suggests that
Figure 2 Correlation between clinical parameters and the expression levels of miR-146a in Tregs in rheumatoid arthritis (RA). Tregs were isolated
and stimulated with anti-CD3/CD28 beads for a total of 2 days. MiRNA expression was assessed in freshly isolated (d0) and in stimulated cells at
24 h (d1) and 48 h (d2) by real-time PCR using TaqMan gene expression assays. MiRNA expression in relation to the expression levels of RNU48 is
demonstrated. Disease activity on 28 Joints (DAS28) (A), swollen joint count on 28 joints (SJC28) and SJC66 (B), tender joint count on 28 joints
(TJC28) and TJC68 (C), C-reactive protein (CRP) (D) and erythrocyte sedimentation rate (ESR) (E) were plotted against the miR-146a expression levels
at d0, d1 and d2. Correlations were determined by Spearman’s rank correlation coefficient.
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changes in the T cell phenotype in response to miR-146a dele-
tion might occur not necessarily only as a result of NF-κB sig-
nalling but also because of augmented expression of other
target genes of miR-146a, like for example, STAT1.27 In our
study, we indeed observed a marked correlation between
miR-146a and STAT1 expression, but not between miR-146a
and IRAK1 or TRAF6 expression (online supplementary figure
S2). IRAK1 and TRAF6 mRNAs were upregulated in patients
with active and non-active disease, while miR-146a expression
was downregulated only in patients with active RA (figures 1C,
3A). Putative binding sites for miR-146a can be predicted in the
30UTR of murine and human IRAK1 and TRAF6 mRNAs.
Moreover, miR-146a-mediated regulation of the expression of
human IRAK1 and TRAF6 has been shown in an in vitro
setting.25 Yet, it might well be that in vivo expression of these
two critical molecules of the NF-κB signalling pathway at least
in humans is subject to a complex and not only to a simplified
miR-146a-mediated switch-on/off regulatory mechanism. In this
regard, Pauley et al19 reported normal IRAK1 and TRAF6
expression in a bulk of mononuclear cells of RA patients despite
the observed 2.6-fold increase in miR-146a expression.
Similar to miR-146a, miR-155 has been reported to be
induced by NF-κB signalling.24 The result of NF-κB-induced
miRNA expression, however, appears to be rather contrary
between miR-146a and miR-155. Whereas miR-146a rather
calms the pro-inflammatory immune response, miR-155
enhances inflammation. Deletion of miR-146a leads to a sizable
proportion of IFNγ-producing CD4 T cells and hyper-
responsiveness of macrophages to LPS.27 35 MiR-146a-deficient
mice spontaneously develop autoimmune disorders.35 MiR-155,
in turn, diminishes the magnitude of the immune response in
macrophages and dendritic cells.32 Mice deficient for miR-155
are biased towards Th2 differentiation and are resistant to
Th17-driven autoimmune inflammation.18 30 31 36 Interestingly,
we did observe these opposite effects of both miRNAs. Tregs
from active RA patients expressed on the one hand increased
levels of STAT1, a target gene of miR-146a, promoting a
pro-inflammatory phenotype of the cells, and on the other hand
elevated levels of SOCS1, a target of miR-155, which negatively
regulates inflammation (figure 4). Additionally, treatment with
mimics and antagomirs led also to opposite effects on cytokine
expression (figure 5A). Nevertheless, the resulting phenotype of
Figure 3 Analysis of NF-κB signalling pathway. (A–C) Tregs were isolated and stimulated with anti-CD3/CD28 beads for a total of 2 days. MRNA
expression was assessed in freshly isolated (d0) and in stimulated cells at 24 h (d1) and 48 h (d2) by real-time PCR using TaqMan gene expression
assays. Relative mRNA expression normalised to the expression levels of ß-actin mRNA is demonstrated. Expression levels of IRAK1 (A), TRAF6 (B)
and IKKɛ (C) in 24 healthy controls and in rheumatoid arthritis (RA) patients grouped according to disease activity: active RA—DAS28 >3.2 (n=8)
and low disease activity—DAS28 ≤3.2 (n=11), are shown as box plots demonstrating minimum, maximum, median and 25th and 75th percentiles.
(D) Isolated Tregs were transfected with an NF-κB reporter vector and stimulated either with anti-CD3/CD28 beads or with phorbol 12-myristat
13-acetat (PMA) and ionomycin. Luciferase activity was analysed 17 h later. Relative luciferase activity from 9 HC and 8 RA patients is shown.
*p<0.05, **p<0.01, ***p<0.001 by Student t test.
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Figure 4 Analysis of STAT1, SOCS1 and cytokine expression. Tregs were isolated and stimulated with anti-CD3/CD28 beads for a total of 2 days.
MRNA expression was assessed in freshly isolated (d0) and in stimulated cells at 24 h (d1) and 48 h (d2) by real-time PCR using TaqMan gene
expression assays. Relative mRNA expression normalised to the expression levels of ß-actin mRNA is demonstrated. Protein expression was assessed
in freshly isolated (d0) and/or in 24 h stimulated (d1) cells by intracellular staining (STAT1) or by ELISA (cytokines). MRNA expression levels of STAT1
and SOCS1 (A) and of IL-2, TNF, IL-17 and IFNγ (C) in 22 healthy controls (HC) and in 19 rheumatoid arthritis (RA) patients are shown as box plots
demonstrating minimum, maximum, median and 25th and 75th percentiles. (B) Expression of total STAT1 protein and of phosphorylated STAT1
(pSTAT1) was assessed as mean fluorescence intensity. Representative stainings are demonstrated in the upper panel. In the lower panel results from
9 HC and 18 RA patients are summarised. (D) TNF, IL-17 and IFNγ at protein level were assessed in cell culture supernatants from 14 HC and 24 RA
patients 24 h after stimulation by ELISA. Patients were stratified according to disease activity: active RA—DAS28 >3.2 and low disease activity—
DAS28 ≤3.2. *p<0.05, **p<0.01, ***p<0.001 by Student t test.
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the Tregs was rather pro-inflammatory in patients with active
disease, as expression of IL-17, TNF and IFNγ was elevated
(figure 4C,D). Thus, it appears as if the pro-inflammatory effect
of reduced miR-146a expression prevails over the counteracting
impact of reduced miR-155 expression, leading to
pro-inflammatory alterations of the phenotype of Tregs in RA.
This became obvious when we interfered with the biological
activity of both miRNAs simultaneously (figure 5A). The
observed diminution of miR-155 expression may, therefore,
reflect an attempt of Tregs to counteract the unwanted
pro-inflammatory STAT1-mediated effects by upregulation of its
natural antagonist, SOCS1.
The preponderance of miR-146 over miR-155 with regard to
their impact on Treg function in RA was reflected by the correl-
ation of miR-146 but not of miR-155 with clinical parameters
of disease activity. Interesting in this regard was the fact that
miR-146a correlated with indicators of local joint inflammation,
for example, TJC and SJC, but not with parameters suggestive
of systemic inflammation, for example, CRP and ESR (figure 2).
This finding suggests that miR-146a-mediated alterations in the
Treg phenotype were of particular importance in synovial
inflammation although it should be noted that no difference in
miR-146a expression levels were detected between Tregs from
the peripheral circulation and matched synovial samples (online
Figure 5 Effect of miR-146a and miR-155 on Treg cytokine production and suppressive capacity. Tregs were isolated, transfected with mimics or
antagomirs of miR-146a or miR-155 and (A, B) stimulated with anti-CD3/CD28. 24 h after stimulation IFNγ, TNF and IL-17 were assessed in cell
culture supernatants by ELISA (A) or expression and phosphorylation status of STAT1 (total STAT1 and pSTAT1, respectively) were assessed
intracellularly based on mean fluorescence intensity (B). Data are shown as fold changes normalised to cells transfected with scrambled (scr) oligos.
Mean±SD of 3 to 10 experiments are shown. (C) To verify the effect of intervention with miRNA activity on the suppressive capacity of Tregs,
CD25 negative CD4 T cells were isolated additionally, and labelled with CFSE. Transfected Tregs were cultured with CFSE-labelled CD25 negative CD4 T
cells in a 1:1 ratio in the presence of anti-CD3 and feeder cells for 4 days. Proliferation of CD25 negative CD4 T cells was assessed by flow cytometry
based on CFSE dilution. One representative experiment of three experiments is depicted. * p<0.05, ** p<0.01, *** p<0.001 by Student t test.
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supplementary figure S4). In this regard, it is interesting that
diminution of miR-146a (as of miR-155) expression became
only evident in response to activation indicating that the effect
of these alterations strikes primarily during an ongoing immune
response like, for example, local inflammation in the joint. By
contrast, systemic inflammation appears to be less dependent on
Treg function. In accordance with our finding, Tang et al21 have
observed that in CIA, systemic administration of an analogue to
miR-146a prevented joint destruction but failed to completely
ameliorate inflammation. Likewise, in lupus, decreased levels of
miR-146a in leukocytes were also associated with kidney inflam-
mation, a prominent organ manifestation in lupus, but not with
systemic inflammatory activity.37
Our data on miR-146a expression appear to be in contrast to
a publication by Li et al20 reporting increased expression of
miR-146a in CD4 T cells from patients with RA. The patient
cohort analysed in that paper is, however, different to ours. The
patients from the previous study had long-lasting disease
(∼5 years), very active RA (DAS28 6.35±1.45), and yet were
DMARD naive. By contrast, the untreated patients included in
our study had symptoms of the disease for less than 1 year (8.2
±11.2 months) and a DAS28 of 5.02±1.13. It might be specu-
lated that long-lasting inflammation without any treatment in
the patients analysed by Li et al might have led to secondary
events influencing the miRNA expression profile that are not
related to primary Treg alterations in RA. The fact that Li et al
observed extremely elevated ESR (67.94±21.19 mm/h) may
support this hypothesis. On the other hand, we cannot com-
pletely exclude that the glucocorticoide or the antirheumatic
therapy might at least in part have influenced results of our
study. The preliminary observation that anti-TNF-treatment was
associated with a change in miR-146a levels may support this
notion (online supplementary figure S4). In any case, the strong
correlation between miR-146a expression and disease activity
independent of the therapy observed by us (figure 2) argues for
a direct dependence of miRNA expression in Tregs and disease
activity.
The pro-inflammatory phenotype of Tregs characterised by
enhanced cytokine production in RA was also observed by
others.38 Inflammatory conditions might force Tregs to become
unstable and adopt a phenotype that is more characteristic of
effector CD4 T cells during the evolution of an autoimmune
disease.39 40 Altered expression of miR-146a in RA Tregs might
thus be the molecular correlate of such phenotypic alterations
of Tregs. As reduced expression of miR-146a was particularly
prominent in patients with early, treatment-naive RA patients
and in patients with active disease, but not in patients with well-
controlled or long-standing disease, our observation might
argue for a role of diminished Treg function during disease
onset and in disease flairs. Moreover, they might argue for a
Treg control of autoimmune inflammation at rather local, organ-
specific sites and not at the level of systemic inflammation. Our
findings indicate that a deregulated miRNA expression in Tregs
might lead to harmful alterations in their phenotype and
provide, therefore, novel indications for the involvement of
miR-146a and miR-155 in RA pathogenesis.
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